Skip to content

Tempus Pro Monitor Registry

A Post Market Clinical Follow-up Study to Evaluate the Safety and Clinical Performance of the Tempus Pro, a Multi-parameter Vital Signs Monitoring Device With Specific Reference to ECG Recordings and Data Transmission Using Telemedicine

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05587764
Enrollment
103
Registered
2022-10-20
Start date
2024-04-25
Completion date
2024-08-12
Last updated
2026-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emergency Care, Sudden Cardiac Arrest

Keywords

Tempus Pro, IntelliSpace Corsium

Brief summary

A multicenter, prospective and retrospective, observational, post market study.

Detailed description

This observational study is to collect real-world data on the safety and performance of the Tempus Pro device, its accessories and the IntelliSpace Corsium telemedicine software device when used according to its intended purpose and the instructions for use, when used for patient monitoring.

Interventions

DIAGNOSTIC_TESTStandard of Care

Standard of care for emergency events per local guidelines.

Sponsors

Heartstream US LLC
Lead SponsorINDUSTRY
Philips Clinical & Medical Affairs Global
CollaboratorINDUSTRY
North American Science Associates Ltd.
CollaboratorNETWORK

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Patients monitored by using Tempus Pro during pre-hospital care (ambulance transportation) One or more 12-lead ECG recorded Use of 3 or more of the following sensors to measure vital signs * NIBP (Non-Invasive Blood Pressure) * HR (Heart Rate) * SpO2 (Oxygen Saturation) * PVI (Pleth Variability Index) * SpCO (Carboxyhemoglobin) * SpOC (Oxygen Content) * SpHb (Total Hemoglobin) * SpMet (Methemoglobin Saturation) * EtCO2 (End-tidal Carbon Dioxide)

Exclusion criteria

* None defined

Design outcomes

Primary

MeasureTime frameDescription
Clinician assessment of 12-lead ECG reportsthrough study completion, an average of 1 yearThe proportion of 12-lead ECG pairs that are identical, after a cardiologist's review of printouts from Corsium IntelliSpace (transmitted) ECG and the original ECG from the Tempus Pro device.
Diagnostic quality of 12-leadthrough study completion, an average of 1 yearThe printed patient record ECG will be independently reviewed for abnormalities and distortion by a clinician. The clinician will note any abnormalities altering diagnostic quality.
Consistency of transmitted vital signs by Tempus Pro via IntelliSpace Corsiumthrough study completion, an average of 1 yearThe number and proportion of patient vital sign data points, comparing direct data with identical units of measure from printouts from IntelliSpace Corsium (transmitted) vital signs and the original vital signs from the Tempus Pro device.

Secondary

MeasureTime frameDescription
Number of all activated alarmsthrough study completion, an average of 1 yearThe 'Summary Record of Care' indicates all alarms - for all alarm-settable parameters - were activated at the thresholds set by the user, as indicated in the 'Technical Log'
IntelliSpace Corsium transmissionthrough study completion, an average of 1 yearThe Summary Record of Care (SRoC) data transmission from Tempus Pro to IntelliSpace Corsium will be independently reviewed for abnormalities and distortion by a clinician. The clinician will note any abnormalities altering diagnostic quality of the transmission.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORRichard Lyon, MB CHB (HONS) MD MRCP FRCEM

CONSULTANT IN EMERGENCY MEDICINE, NHS LOTHIAN

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 22, 2026